JP2020524510A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020524510A5 JP2020524510A5 JP2019570555A JP2019570555A JP2020524510A5 JP 2020524510 A5 JP2020524510 A5 JP 2020524510A5 JP 2019570555 A JP2019570555 A JP 2019570555A JP 2019570555 A JP2019570555 A JP 2019570555A JP 2020524510 A5 JP2020524510 A5 JP 2020524510A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- polypeptide
- binding
- fixa
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims 20
- 239000000427 antigen Substances 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 101150117115 V gene Proteins 0.000 claims 2
- 238000005215 recombination Methods 0.000 claims 2
- 230000006798 recombination Effects 0.000 claims 2
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 230000035602 clotting Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 238000005734 heterodimerization reaction Methods 0.000 claims 1
- 125000001165 hydrophobic group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1709970.6 | 2017-06-22 | ||
| GBGB1709970.6A GB201709970D0 (en) | 2017-06-22 | 2017-06-22 | Bispecific antigen-binding molecules |
| PCT/EP2018/066836 WO2018234575A1 (en) | 2017-06-22 | 2018-06-22 | Bispecific antibodies for factor ix and factor x |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020524510A JP2020524510A (ja) | 2020-08-20 |
| JP2020524510A5 true JP2020524510A5 (OSRAM) | 2021-07-29 |
| JP7378298B2 JP7378298B2 (ja) | 2023-11-13 |
Family
ID=59523569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570555A Active JP7378298B2 (ja) | 2017-06-22 | 2018-06-22 | 第ｉｘ因子および第ｘ因子に対する二重特異性抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11919969B2 (OSRAM) |
| EP (1) | EP3642244A1 (OSRAM) |
| JP (1) | JP7378298B2 (OSRAM) |
| CN (1) | CN110753704B (OSRAM) |
| GB (1) | GB201709970D0 (OSRAM) |
| WO (1) | WO2018234575A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3126384B1 (en) * | 2014-04-01 | 2020-12-02 | Adimab, LLC | Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use |
| CN110248964B (zh) | 2017-02-01 | 2024-08-27 | 诺和诺德股份有限公司 | 促凝血抗体 |
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| US11220554B2 (en) | 2018-09-07 | 2022-01-11 | Novo Nordisk A/S | Procoagulant antibodies |
| CN113453757B (zh) * | 2018-12-21 | 2024-06-28 | 科马布有限公司 | 具有共同轻链的FIXaxFX双特异性抗体 |
| GB2590642B (en) * | 2019-12-20 | 2024-02-14 | Kymab Ltd | Improved lambda antibodies |
| WO2020229621A1 (en) | 2019-05-15 | 2020-11-19 | Kymab Limited | Improved lambda antibodies |
| US20230151115A1 (en) * | 2020-03-31 | 2023-05-18 | University Public Corporation Osaka | Multispecific antibody and method for producing same |
| IL298632A (en) * | 2020-06-02 | 2023-01-01 | Biocytogen Pharmaceuticals Beijing Co Ltd | Non-human animals genetically modified with a common light chain immunoglobulin locus |
| CN114113602B (zh) * | 2020-08-28 | 2024-07-02 | 香港城市大学深圳研究院 | 免疫球蛋白相关凝血因子x作为急性心肌梗死的生物标志物 |
| AR129879A1 (es) * | 2022-07-08 | 2024-10-09 | Novo Nordisk As | Compuestos de isvd altamente potentes capaces de sustituir al fviii(a) |
| CN116589588B (zh) * | 2023-04-14 | 2023-12-22 | 北京基科晟斯医药科技有限公司 | 结合凝血因子x的抗体 |
| CN116333145B (zh) * | 2023-04-14 | 2023-11-07 | 北京基科晟斯医药科技有限公司 | 结合活化凝血因子ix的抗体 |
| GB202316779D0 (en) * | 2023-11-01 | 2023-12-13 | Ucl Business Ltd | Antigen binding protein |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| MA24512A1 (fr) * | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
| AU751659B2 (en) | 1997-05-02 | 2002-08-22 | Genentech Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| WO1999003496A1 (en) * | 1997-07-21 | 1999-01-28 | The University Of North Carolina At Chapel Hill | Factor ix antihemophilic factor with increased clotting activity |
| AT411997B (de) * | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
| DK1355919T3 (da) | 2000-12-12 | 2011-03-14 | Medimmune Llc | Molekyler med længere halveringstider, sammensætninger og anvendelser deraf |
| US7297336B2 (en) | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
| WO2005035753A1 (ja) | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
| US20080075712A1 (en) | 2003-10-14 | 2008-03-27 | Kunihiro Hattori | Double Specific Antibodies Substituting For Functional Proteins |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| DK1876236T3 (da) | 2005-04-08 | 2014-10-20 | Chugai Pharmaceutical Co Ltd | Antistof som funktionel erstatning for blodkoagulationsfaktor VIII |
| HRP20120851T1 (hr) | 2005-07-05 | 2012-11-30 | Glaxo Group Limited | Humanizirana protutijela specifiäśna za nogo-a i njihova farmaceutska upotreba |
| CA2646965C (en) | 2006-03-24 | 2016-06-21 | Jonathan H. Davis | Engineered heterodimeric protein domains |
| AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| MX368932B (es) | 2009-06-26 | 2019-10-22 | Regeneron Pharma | Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original. |
| ES2948572T3 (es) | 2009-07-08 | 2023-09-14 | Kymab Ltd | Modelos de roedores y moléculas terapéuticas |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| CA2802591A1 (en) | 2010-06-17 | 2011-12-22 | Kymab Limited | Animal models and therapeutic molecules |
| RU2620071C2 (ru) * | 2010-11-17 | 2017-05-22 | Чугаи Сеияку Кабушики Каиша | Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii |
| US20140356377A1 (en) | 2011-08-25 | 2014-12-04 | Umc Utrecht Holding B.V. | Compounds for use in boosting coagulation |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| CN120383672A (zh) | 2012-04-20 | 2025-07-29 | 美勒斯公司 | 用于产生免疫球蛋白样分子的方法和手段 |
| WO2014058389A1 (en) | 2012-10-12 | 2014-04-17 | Agency For Science, Technology And Research | Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics |
| KR20160070163A (ko) | 2013-11-04 | 2016-06-17 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 출혈 또는 응고성 저하와 관련된 상태의 치료 또는 예방용 요법 |
| RU2016129959A (ru) | 2013-12-30 | 2018-02-02 | Эпимаб Биотерепьютикс Инк. | Иммуноглобулин с тандемным расположением fab-фрагментов и его применение |
| TWI831106B (zh) | 2014-06-20 | 2024-02-01 | 日商中外製藥股份有限公司 | 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物 |
| TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體 |
| MX2017010734A (es) * | 2015-04-17 | 2017-12-04 | Hoffmann La Roche | Terapia de combinacion con factores de coagulacion y anticuepos multiespecificos. |
| JP2018123055A (ja) | 2015-04-24 | 2018-08-09 | 公立大学法人奈良県立医科大学 | 血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｘｉ因子（ｆｘｉ）異常症の予防および／または治療に用いられる医薬組成物 |
| EP3368561B1 (en) | 2015-10-30 | 2025-09-17 | Medimmune Limited | Prevention of n-terminal truncation in igg light chains |
| EP3395835B1 (en) | 2015-12-25 | 2021-02-03 | Chugai Seiyaku Kabushiki Kaisha | Antibody having enhanced activity, and method for modifying same |
| NZ743881A (en) | 2016-02-06 | 2023-11-24 | Epimab Biotherapeutics Inc | Fabs-in-tandem immunoglobulin and uses thereof |
| AU2017268198C1 (en) | 2016-05-16 | 2020-11-26 | Takeda Pharmaceutical Company Limited | Anti-Factor IX Padua antibodies |
| MX2018015721A (es) | 2016-07-29 | 2019-05-27 | Chugai Pharmaceutical Co Ltd | Anticuerpos biespecificos que exhiben actividad de funcion de cofactor fviii alternativa mejorada. |
| JP7125932B2 (ja) | 2016-09-06 | 2022-08-25 | 中外製薬株式会社 | 凝固第ｉｘ因子および／または活性化凝固第ｉｘ因子ならびに凝固第ｘ因子および／または活性化凝固第ｘ因子を認識する二重特異性抗体の使用法 |
| CN110662770A (zh) | 2016-11-23 | 2020-01-07 | 比奥维拉迪维治疗股份有限公司 | 结合凝血因子ix和凝血因子x的双特异性抗体 |
| CN110248964B (zh) | 2017-02-01 | 2024-08-27 | 诺和诺德股份有限公司 | 促凝血抗体 |
| CN110494163A (zh) | 2017-02-06 | 2019-11-22 | 应用干细胞有限公司 | 凝血因子viii模拟蛋白及其用途 |
| EP3621643A4 (en) | 2017-05-11 | 2021-07-21 | Atreca, Inc. | ANTIBODY ANTI-MALARIA BOUND WITH CIRCUMSPOROZOID PROTEIN |
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| EP3690050A4 (en) | 2017-09-29 | 2021-06-16 | Chugai Seiyaku Kabushiki Kaisha | MULTISPECIFIC ANTIGENBINDING MOLECULE WITH BLOOD CLOG FACTOR VIII (FVIII) COFACTOR FUNCTION SUBSTITUATING ACTIVITY AND PHARMACEUTICAL FORMULATION WITH THIS MOLECULE AS THE ACTIVE SUBSTANCE |
| ES3050257T3 (en) | 2017-11-15 | 2025-12-19 | Novo Nordisk As | Factor x binders enhancing fx activation |
| CN113453757B (zh) | 2018-12-21 | 2024-06-28 | 科马布有限公司 | 具有共同轻链的FIXaxFX双特异性抗体 |
-
2017
- 2017-06-22 GB GBGB1709970.6A patent/GB201709970D0/en not_active Ceased
-
2018
- 2018-06-22 CN CN201880040433.6A patent/CN110753704B/zh active Active
- 2018-06-22 EP EP18735237.2A patent/EP3642244A1/en active Pending
- 2018-06-22 WO PCT/EP2018/066836 patent/WO2018234575A1/en not_active Ceased
- 2018-06-22 US US16/625,109 patent/US11919969B2/en active Active
- 2018-06-22 JP JP2019570555A patent/JP7378298B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020524510A5 (OSRAM) | ||
| US11649295B2 (en) | Asymmetric multispecific antibodies | |
| JP2023113686A (ja) | ｐＨ依存的抗体の調製方法 | |
| JP2019527553A5 (OSRAM) | ||
| JP7649744B2 (ja) | Ｂｔｎ３ａ結合タンパク質及びその使用 | |
| JP2020508655A5 (OSRAM) | ||
| JP2012525829A5 (OSRAM) | ||
| NZ601583A (en) | Novel rabbit antibody humanization methods and humanized rabbit antibodies | |
| JP2012518425A5 (OSRAM) | ||
| HRP20201191T1 (hr) | Mutirani multispecifični fab fragmenti antitijela | |
| JP2010502183A5 (OSRAM) | ||
| JP2015519375A5 (OSRAM) | ||
| JP2020514277A5 (OSRAM) | ||
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| JP2011505810A5 (OSRAM) | ||
| JP2019502694A5 (OSRAM) | ||
| JP2013535191A5 (OSRAM) | ||
| JP2021502984A5 (OSRAM) | ||
| JP2017521054A5 (OSRAM) | ||
| JP2020515277A5 (OSRAM) | ||
| JP2017509323A5 (OSRAM) | ||
| JP2020522475A5 (OSRAM) | ||
| JP2018515453A5 (OSRAM) | ||
| CN109721656B (zh) | 靶向rankl的治疗性抗体 | |
| FI4031569T3 (fi) | Kantasolutekijän vasta-aineet ja niiden käyttömenetelmät |